NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free ELVN Stock Alerts $17.59 -1.04 (-5.58%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$17.36▼$18.6950-Day Range$11.54▼$19.2152-Week Range$9.80▼$24.22Volume196,400 shsAverage Volume157,752 shsMarket Capitalization$724.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enliven Therapeutics alerts: Email Address Enliven Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestBearish20.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 8 Articles This WeekInsider TradingSelling Shares$8.98 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.09 out of 5 starsMedical Sector586th out of 939 stocksPharmaceutical Preparations Industry278th out of 441 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $0.00, Enliven Therapeutics has a forecasted downside of 100.0% from its current price of $17.59.Amount of Analyst CoverageEnliven Therapeutics has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.43% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 30.6, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELVN. Previous Next 3.7 News and Social Media Coverage News SentimentEnliven Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Enliven Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for ELVN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,983,658.00 in company stock.Percentage Held by Insiders45.80% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Enliven Therapeutics Stock (NASDAQ:ELVN)Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.Read More ELVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELVN Stock News HeadlinesMarch 28, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 SharesMarch 22, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 SharesMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 11, 2024 | insidertrades.comAnish Patel Sells 4,875 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMarch 29, 2024 | americanbankingnews.comSamuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMarch 29, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 3% After Insider SellingMarch 28, 2024 | globenewswire.comEnliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024March 21, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up to $12.64March 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 19, 2024 | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesMarch 19, 2024 | msn.comEnliven Therapeutics announces $90M private placement to fund R&D activitiesMarch 19, 2024 | globenewswire.comEnliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesMarch 15, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)March 14, 2024 | investorplace.comELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023March 14, 2024 | globenewswire.comEnliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateMarch 11, 2024 | msn.comVentyx stock tumbles 18% amid pipeline updatesFebruary 27, 2024 | finance.yahoo.comEnliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceFebruary 27, 2024 | globenewswire.comEnliven Therapeutics to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 17, 2024 | finance.yahoo.comELVN Mar 2024 20.000 callFebruary 12, 2024 | seekingalpha.comEnliven Therapeutics Maybe Improving Kinase Inhibitors, But Too Early To Tell The ImpactJanuary 3, 2024 | finance.yahoo.comEnliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 SharesNovember 11, 2023 | benzinga.comEnliven Therapeutics Stock (NASDAQ:ELVN) Earnings Dates and Earning CallsNovember 10, 2023 | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Enliven Therapeutics (ELVN)November 9, 2023 | msn.comEnliven Therapeutics GAAP EPS of -$0.51November 9, 2023 | finance.yahoo.comEnliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 9, 2023 | morningstar.comEnliven Therapeutics Inc ELVNSee More Headlines Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELVN CUSIPN/A CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside+53.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.56% Return on Assets-25.18% Debt Debt-to-Equity RatioN/A Current Ratio10.28 Quick Ratio10.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book2.95Miscellaneous Outstanding Shares41,200,000Free Float22,330,000Market Cap$724.71 million OptionableOptionable Beta1.05 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Comp: $597kMr. Benjamin Hohl (Age 35)CFO & Head of Corporate Development Comp: $488.5kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Comp: $558kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder, Chief Scientific Officer & Directors Mr. Anish Patel Pharm.D. (Age 44)Co-Founder & COO Dr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More ExecutivesKey CompetitorsLongboard PharmaceuticalsNASDAQ:LBPHPharming GroupNASDAQ:PHARBicycle TherapeuticsNASDAQ:BCYCAurinia PharmaceuticalsNASDAQ:AUPHZymeworksNYSE:ZYMEView All CompetitorsInsiders & InstitutionsSamuel KintzSold 12,000 sharesTotal: $210,720.00 ($17.56/share)Richard A HeymanSold 1,270 sharesTotal: $18,415.00 ($14.50/share)Vanguard Group Inc.Bought 79,071 shares on 3/11/2024Ownership: 2.987%Anish PatelSold 4,875 sharesTotal: $76,245.00 ($15.64/share)Goldman Sachs Group Inc.Bought 5,008 shares on 3/1/2024Ownership: 0.055%View All Insider TransactionsView All Institutional Transactions ELVN Stock Analysis - Frequently Asked Questions Should I buy or sell Enliven Therapeutics stock right now? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ELVN shares. View ELVN analyst ratings or view top-rated stocks. What is Enliven Therapeutics' stock price target for 2024? 0 brokers have issued twelve-month price targets for Enliven Therapeutics' stock. Their ELVN share price targets range from $10,000,000.00 to $0.00. On average, they predict the company's stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts. How have ELVN shares performed in 2024? Enliven Therapeutics' stock was trading at $13.84 at the beginning of the year. Since then, ELVN shares have increased by 27.1% and is now trading at $17.59. View the best growth stocks for 2024 here. When is Enliven Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELVN earnings forecast. Who are Enliven Therapeutics' major shareholders? Enliven Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Citadel Advisors LLC (5.81%), Vanguard Group Inc. (2.99%), Vanguard Group Inc. (2.99%), Northern Trust Corp (0.55%), Charles Schwab Investment Management Inc. (0.38%) and Barclays PLC (0.10%). Insiders that own company stock include 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Richard A Heyman and Samuel Kintz. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELVN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.